Clinical Trial Update: Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum [Phase 2]

View source ↗

Summary

Phase 2 trial of aminocamptothecin in recurrent or refractory ovarian epithelial cancer and primary peritoneal cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Aminocamptothecin (aminocamptothecin)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED